After whisking through Washington for the first half of the year, raising alarms, mutating and causing confusion, the Biosecure Act is now on pause. On the latest BioCentury This Week podcast, BioCentury’s editors discuss what the delay for the legislation, which seeks to drive Chinese contract development and manufacturing organizations out of the U.S., means, what will happen next, and how it will impact life sciences companies.
View full story: https://www.biocentury.com/article/652771
03:09 - What's In, What's Out
05:41 - Broader Impact
11:07 - Wake-up Call
Fler avsnitt av BioCentury This Week
Visa alla avsnitt av BioCentury This WeekBioCentury This Week med BioCentury finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.
